<DOC>
	<DOCNO>NCT00049634</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug donor peripheral blood stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving colony-stimulating factor , G-CSF , donor help stem cell move bone marrow blood collect store . PURPOSE : This phase I/II trial study well donor peripheral stem cell transplant work treat patient myelodysplastic syndrome , acute myeloid leukemia , myeloproliferative disorder .</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Transplant Treating Patients With Myelodysplastic Syndrome , Acute Myeloid Leukemia , Myeloproliferative Disorder</brief_title>
	<detailed_description>OBJECTIVES : - Determine incidence grade II , III , IV graft-vs-host disease ( GVHD ) patient myelodysplastic syndrome ( MDS ) , acute myeloid leukemia transform MDS , myeloproliferative disorder treat immunologically engineer , filgrastim ( G-CSF ) -mobilized , allogeneic peripheral blood stem cell transplantation . - Determine incidence graft failure , relapse , transplant-related mortality day 100 patient treated regimen . - Determine incidence chronic GVHD , term number duration immunosuppressant therapy , patient treat regimen . - Determine feasibility partial T-cell depletion G-CSF-mobilized peripheral blood stem cell . OUTLINE : Patients receive condition oral busulfan every 6 hour day -7 -4 cyclophosphamide IV day -3 -2 . Immunologically engineer , filgrastim ( G-CSF ) -mobilized , allogeneic peripheral blood stem cell infuse day 0 . Patients receive graft-vs-host disease prophylaxis comprise methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV 1-4 hour ( orally twice daily tolerate ) day -1 80 gradually taper 5 month begin day 81 . Patients follow regularly day 100 1 year . PROJECTED ACCRUAL : A total 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Myelodysplastic syndrome ( MDS ) advance beyond refractory anemia ( RA ) RA excess blast ( RAEB ) ( great 5 % blast ) RAEB transformation ( great 20 % le 30 % blast ) Acute myeloid leukemia ( great 30 % blast ) evolve MDS Myeloproliferative disorder , include chronic myelomonocytic leukemia , agnogenic myeloid metaplasia , polycythemia vera , essential thrombosis No chronic myelogenous leukemia without excess ( great 5 % ) blast Must HLAidentical , related donor PATIENT CHARACTERISTICS : Age 18 65 Performance status Not specify Life expectancy At least 6 month Hematopoietic Not specify Hepatic Bilirubin less 2 time upper limit normal ( ULN ) * SGOT/SGPT le 2 time ULN* NOTE : * Unless due malignancy Renal Creatinine great 2.0 mg/dL OR Glomerular filtration rate least 60 mL/min Cardiovascular Cardiac ejection fraction least 45 % Pulmonary DLCO least 60 % predict Other HIV negative Human antimouse antibody negative Not pregnant nursing Fertile patient must use effective contraception No medical condition would preclude study participation No hypersensitivity cyclosporine PRIOR CONCURRENT THERAPY : Biologic therapy No prior marrow transplantation No concurrent growth factor 21 day study transplantation Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>